GlassScriptPhysician profile
Tamara M Barlage
NPI 1831771336
$5,650.76
in general payments reported to CMS, 2019-2025
40 companies · $2,080 in 2025
The $2,080 reported for 2025 was more than what 95% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $164 · 2022: $636 · 2023: $1,192 · 2024: $1,579 · 2025: $2,080.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,851.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,851.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,301.10 | 2022-2025 | |
| Lilly USA, LLC | $548.25 | 2022-2025 | Kisunla, Amyvid, Emgality |
| Neurocrine Biosciences, INC. | $410.49 | 2022-2025 | Ingrezza, Ongentys |
| Ucb, INC. | $388.22 | 2022-2025 | Briviact, Zilbrysq, Fintepla |
| Pfizer INC. | $275.89 | 2022-2025 | |
| Alexion Pharmaceuticals, INC. | $225.31 | 2024-2025 | Ultomiris, Soliris |
| Argenx US, INC. | $207.91 | 2023-2025 | Vyvgart Hytrulo, Vyvgart |
| Sk Life Science, INC. | $205.05 | 2022-2025 | |
| Axsome Therapeutics, INC. | $178.65 | 2025 | Symbravo |
| Genentech USA, INC. | $178.52 | 2024-2025 | Ocrevus, Ocrevus Zunovo, Enspryng |
| Takeda Pharmaceuticals U.S.A., INC. | $144.78 | 2024-2025 | Hyqvia, Alunbrig |
| Amgen INC. | $142.45 | 2021-2023 | Aimovig |
| Eisai INC. | $137.76 | 2025 | |
| Acadia Pharmaceuticals INC | $127.29 | 2022-2025 | Nuplazid |
| Jazz Pharmaceuticals INC. | $109.96 | 2021-2023 |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tamara Barlage listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.